234 related articles for article (PubMed ID: 26352389)
1. Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue.
Fassunke J; Haller F; Hebele S; Moskalev EA; Penzel R; Pfarr N; Merkelbach-Bruse S; Endris V
Int J Mol Med; 2015 Nov; 36(5):1233-43. PubMed ID: 26352389
[TBL] [Abstract][Full Text] [Related]
2. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of different massive parallel sequencing platforms for mutation profiling in formalin-fixed and paraffin-embedded samples].
Jiang RR; Wang YJ; Teng XD; Xiao L; Bu H; Ye F
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):591-596. PubMed ID: 30107663
[No Abstract] [Full Text] [Related]
4. Detection of EGFR mutations in patients with non-small cell lung cancer by high resolution melting. Comparison with other methods.
Martínez-Carretero C; Pascual FI; Rus A; Bernardo I
Clin Chem Lab Med; 2017 Oct; 55(12):1970-1978. PubMed ID: 28432840
[TBL] [Abstract][Full Text] [Related]
5. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
[TBL] [Abstract][Full Text] [Related]
6. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.
Endris V; Penzel R; Warth A; Muckenhuber A; Schirmacher P; Stenzinger A; Weichert W
J Mol Diagn; 2013 Nov; 15(6):765-75. PubMed ID: 23973117
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
[TBL] [Abstract][Full Text] [Related]
8. Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens.
Xu H; Sun W; Zhang G; Cheng Y
J BUON; 2015; 20(1):142-5. PubMed ID: 25778309
[TBL] [Abstract][Full Text] [Related]
9. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
[TBL] [Abstract][Full Text] [Related]
10. Validation of an Ion Torrent Sequencing Platform for the Detection of Gene Mutations in Biopsy Specimens from Patients with Non-Small-Cell Lung Cancer.
Fujita S; Masago K; Takeshita J; Okuda C; Otsuka K; Hata A; Kaji R; Katakami N; Hirata Y
PLoS One; 2015; 10(6):e0130219. PubMed ID: 26076009
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
[TBL] [Abstract][Full Text] [Related]
12. A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.
Sakamoto T; Kodani M; Takata M; Chikumi H; Nakamoto M; Nishii-Ito S; Ueda Y; Izumi H; Makino H; Touge H; Takeda K; Yamasaki A; Yanai M; Tanaka N; Igishi T; Shimizu E
Int J Oncol; 2015 Apr; 46(4):1473-80. PubMed ID: 25651992
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
14. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
[TBL] [Abstract][Full Text] [Related]
15. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
[TBL] [Abstract][Full Text] [Related]
16. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
Fassunke J; Ihle MA; Lenze D; Lehmann A; Hummel M; Vollbrecht C; Penzel R; Volckmar AL; Stenzinger A; Endris V; Jung A; Lehmann U; Zeugner S; Baretton G; Kreipe H; Schirmacher P; Kirchner T; Dietel M; Büttner R; Merkelbach-Bruse S
Virchows Arch; 2017 Oct; 471(4):509-520. PubMed ID: 28884371
[TBL] [Abstract][Full Text] [Related]
17. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
Deeb KK; Hohman CM; Risch NF; Metzger DJ; Starostik P
Arch Pathol Lab Med; 2015 Jul; 139(7):913-21. PubMed ID: 26125431
[TBL] [Abstract][Full Text] [Related]
18. Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis.
Hu C; Liu X; Chen Y; Sun X; Gong Y; Geng M; Bi L
Oncol Rep; 2012 Nov; 28(5):1815-21. PubMed ID: 22923193
[TBL] [Abstract][Full Text] [Related]
19. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
[TBL] [Abstract][Full Text] [Related]
20. Microfluidics-based EGFR mutation detection and its implication in the resource-limited clinical setting.
Joshi P; Gogte P; Pai T; Gurav M; Dhanawade D; Karnik N; Deshpande G; Kaushal R; Shetty O
Int J Exp Pathol; 2024 Jun; 105(3):90-99. PubMed ID: 38717047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
